1. BEGIN the OneSearch category that includes the fulltext market research reports to search these reports together.

2. Use the (S) operator to SELECT a brand name drug in the same paragraph as sales.

Focus on a market by searching market terms in the main report title or in the section title fields (/MT,TI).

3. Restrict retrieval to articles published within the last two years using the Publication Year (PY=) field. The colon (:) acts as OR.

?B MARKETFU

SYSTEM:OS  - DIALOG OneSearch
  File 759:Business Insights 1992-2007/Nov
         (c) 2007 Datamonitor
  File 763:FREEDONIA MARKET RES. 1990-2007/MAY
         (c) 2007 FREEDONIA GROUP INC.
  File 764:BCC Market Research 1989-2007/Nov
         (c) 2007 Business Communication Co.
  File 767:Frost & Sullivan Market Eng  2007/Dec 11
         (c) 2007 Frost & Sullivan Inc.

      Set   Items  Description
      ---   -----  -----------

?S LIPITOR(S)SALES  AND (STATIN? OR CARDIO? OR CHOLESTEROL)/MT,TI
            1491  LIPITOR
          422963  SALES
             982  LIPITOR(S)SALES
             321  STATIN?/MT,TI
            7886  CARDIO?/MT,TI
             335  CHOLESTEROL/MT,TI
      S1     225  LIPITOR(S)SALES AND (STATIN?  OR CARDIO? OR 
                  CHOLESTEROL)/MT,TI

?S S1 AND  PY=2006:2007
             225  S1
          462731  PY=2006 : PY=2007 
      S2      89  S1 AND PY=2006:2007

4. TYPE out some records in a short format first, such as 8,K. KWIC (K) shows a window of text surrounding your search term. Check the Bluesheets for rates on KWIC in the fulltext market research report databases.

Each record retrieved is one page or section of a report. The top line shows the title of the page or section. The second line contains the title of the full report from which this page comes. The first record comes from File 759, Business Insights, published by Datamonitor January 1, 2007.

You can TYPE out records of interest in Format 9, which is the Full format. TYPE S2/9/1 will display the first record in Set 2 in the Full format.

To select the appropriate record number, look at the range of records in the TYPE command (e.g., 2/8,k/1).

Note: Some records have been omitted from this display.

?T S2/8,K/1-5
        2/8,K/1  (Item 1 from file: 759) 
  DIALOG(R)File 759: Business  Insights
  (c) 2007 Datamonitor. All rights reserved.
  
  00139001 
  5.3 LEADING PLAYERS IN THE  CARDIOVASCULAR MARKET: PFIZER 
  Main Title: THE CARDIOVASCULAR  MARKET OUTLOOK TO 2011 
  Publication Date: January 01,   2007 
  Word Count: 1069 ( 2 pp.) 
  
  * FOR FULL TEXT, USE FORMAT 9 * 
  Features: TABLE 
  Country: WORLD 
  Industry: HEALTH CARE 
  
  Company Names (DIALOG Generated): Esperion Therapeutics ; 
ETC ; Pfizer ;  Schering AG 
  
  Pfizer's marketed products are shown in [Graphic]. 65% 
of Pfizer's cardiovascular sales in  2005 were from  
Lipitor  (atorvastatin), with sales  of over $12.8bn, an 
increase of 6.7% from the  previous year. Pfizer also saw 
extremely high growth of over 300% in  2005 for Caduet 
(combination Lipitor  and  Norvasc), which is an attempt 
to prevent revenue loss prior to the patent  expiry of 
Norvasc and  Lipitor  in 2007 and 2010, respectively. 
Generic  competition for Norvasc and  Lipitor  are 
expected to be vast as they currently  have a wide 
patient potential, and thus Pfizer's sales will be 
heavily impacted. Pfizer had  intended to launch an 
additional dyslipidemic, torcetrapib, in combination with  
Lipitor as a further  revenue protection strategy ahead 
of  Lipitor's patent expiry.

However,  torcetrapib, which was in phase III clinical 
trials, was discontinued  following...

...atherosclerotic  vascular events in patients with ACS; 
  Cardiovascular  portfolio sales  forecasts  Pfizer's 
cardiovascular  portfolio sales forecast  is shown in 
[Graphic] and indicates growth in the marketed portfolio 
until  2007, with strong sales  of  Lipitor   driving 
growth. Due to the anticipated patent expiry of  Lipitor 
and Norvasc  within the forecast period and a lack of new 
product launches, sales are predicted to decline  to 
$14.8bn in 2011...

...20,589   19,173    14,854

Source  : Business Insights; IMS   Business  Insights Ltd

Strategic  analysis

 Sales of Pfizer's currently marketed cardiovascular 
portfolio  are forecast to decline, however the launch 
of... ...in 2004 has the potential  to prevent major 
revenue loss come the patent expiration of Lipitor and 
Norvasc, but  will not be able to revive growth in the 
franchise over the forecast period. Sales of products  
acquired from Esperion's pipeline should allow Pfizer 
to remain a leading cardiovascular...

...forecast  to see high growth rates continue until 
the patent expiry of Lipitor and Norvasc.

 Lipitor (atorvastatin), helped by the 2007  approval 
of its combination with torcetrapib, will continue 
drive Pfizer...

5. REPORT S#/TITLES to view the list of fulltext reports from which the retrieved records came.

The reports appear by publication date, with the most recent reports first. Notice that some reports can have hundreds of pages.

The REPORT TITLES list shows the main title, the database, the publication date and the number of pages in the report.

6. REPORT TITLES places you in a menu. Follow the prompts to choose the report from which you want to view a table of contents. You can browse more titles by entering the letter P for next page or enter the number of a report.

7. Enter C to view a table of contents for the selected report.

8. Enter the number(s) of the page you wish to display.

?REPORT S2/TITLES

Report  not available in file 7

    DIALOG(R) ONLINE TABLE OF CONTENTS
              LIST OF REPORT TITLES

Item           Main Title 
  ------------------------------------------------------
1   CONTRACT PHARMACEUTICAL MANUFACTURING,  RESEARCH, AND PACKAGING
    F0764: BCC Research
    August     2007/167 records
    
2   Key products and competitors of Merck &  Co.
    F0761: DATAMONITOR
    May        2007/5 records
    
3   Analysis of potential future cardiovascular  blockbusters
    F0759: DATAMONITOR
    April      2007/5 records
    
4   ANALYSIS OF THE GLOBAL CARDIOVASCULAR MARKET
    F0759: DATAMONITOR
    April      2007/9 records
    
Enter one item number, P for next page, or EXIT to  leave TITLES:

?. 2
  Enter  (S)ection Headings only, (C)omplete table of contents, 
  M to  return to Main Menu Listing or EXIT to leave TITLES:

?. C
    
          DIALOG(R) F0761: DATAMONITOR
                         Table of Contents
   
Main  Title: Key products and competitors of Merck & Co.
Date:       May        2007
  -------------------------------------------------------------
  KEY  PRODUCTS AND COMPETITORS
  1   KEY FINDINGS; AN=00193658
  2   OVERVIEW; SF=TABLE; AN=00193659
  3   CARDIOVASCULAR; SF=TABLE; AN=00193660
  4   RESPIRATORY; AN=00193661
  5   R&D PIPELINE; SF=TABLE; AN=00193662

Enter item number(s) (e.g. 1,4,6-10) only, C to  repeat Table 
of Contents, M to return to Main Title Listing or EXIT to 
leave  TITLES:

?. 3

9. Enter D to display the record(s).

Note: Large portions of this record are omitted from the display.

Enter D to display records on your screen. For delivery to
previously SET  ADDRESSes, enter E for email or enter an 
existing alternate address name (e.g.,  ADSITE2).

Press  (ENTER) to return to menus or EXIT to leave TITLES:

?. D
          
        00193660
        KEY PRODUCTS AND COMPETITORS:  CARDIOVASCULAR 
        Main Title: Key products and competitors of Merck & Co. 
        Publication Date: May 22,   2007 
        Source: DATAMONITOR 
        Telephone: +44 20 7675 7000 
        Word Count: 4763 ( 7 pp.) 
        Language: English  
        1.2.1.1  Zetia/Vytorin

1.2.1.2  Overview

Zetia/Vytorin:  overview

                             US                     6MM

Brand  name           Zetia/Vytorin          Zetia/Vytorin

International              n/a   
      product code 

Generic  name         ezetimibe/ezetimibe  +  ezetimibe/ezetimibe+
                             simvastatin            simvastatin

ATC3  code                 C10A                   C10A

ATC3  name                 Statins                Statins
  (...)
        1.2.1.3  Sales forecast

Note:  Sales for Vytorin and Zetia were allocated to 
Schering-Plough and Merck &  Co using a 50:50 split across all 
of the 7MM. Total sales for these products  are thus double 
those indicated.

      
(...)

1.2.1.4  Newsflow

Zetia/Vytorin:  news flow
  Date          Event                                  Source
  05  October    The US FDA approved new labeling  for   Merck & Co
  2006          Vytorin , which includes data         press release 
              demonstrating that Vytorin  is more
              effective than Crestor at  reducing
(.... Several  news releases not shown.)

1.2.1.5  Profile

Zetia  recorded sales of $651m in 2005, a 37.7% increase on 2004 
sales of $473m.  Vytorin sales were $487m in 2005 up $430m on 2004 
sales of 56.7%. Zetia is  forecast strong growth over the forecast 
period with a 2005 11 CAGR of 16.2% or  an absolute growth of 
$955m between 2005 and 2011. The majority of the absolute  growth 
will come from the US  market while the 6MM 
  (....)
  Zetia and Vytorin’s main competitors  are Pfizer’s Lipitor, 
Merck & Co.’s Zocor and Bristol Myers Squibb’s  Pravachol, all 
statins, with sales of $10.8 billion, $4.9 billion and $2.0  
billion. The market for anti-cholesterol drugs was approximately 
$25.5 billion  in 2005 up 5.4% on 2004 where the market reached 
$24.2 billion (MIDAS Sales  Data, IMS Health, April 2006). 
  (....)
  Pfizer’s  second-generation statin, Lipitor  (atorvastatin), 
which was launched in 1997. Lipitor has rapidly gained a 
significant share of  the market and annual sales have 
subsequently grown to over $12 billion (company  reported 
revenues), positioning the drug as the world’s best selling 
drug and  the leading product in the statin market by some 
margin.

(....)

....further  $6 billion is likely to be lost as generic 
versions of atorvastatin experience  strong uptake at the 
expense of the remaining branded statins and the generics  
already available on the market.

THIS IS THE FULL-TEXT. 
      
Copyright Datamonitor 2007 

Features: TABLE 
Country: WORLD 
Industry: HEALTH CARE 

10. Exit REPORT TITLES.

Company  Names (DIALOG Generated): ACE ; ARB ; Banyu ; Bristol 
Myers Squibb ; Diabetes ;  Hyzaar and Co ; IMS Health ; Lipitor  
Merck & Co ; Merck & Co ; MIDAS Sales Data ; Pfizer ; Schering 
Plough ;  United Health Group 

This  is the end of the record(s) you requested.  =
        ------------------------------------------------
Enter  item number(s) (e.g. 1,4,6-10) only, C to repeat Table 
of Contents, M to  return to Main Title Listing or EXIT to 
leave TITLES:

? EXIT
        Leaving  Report/TITLES...